BridgeBio Pharma, Inc. Operating Lease Cost
BridgeBio Pharma, Inc. (BBIO) reported Operating Lease Cost of $1.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-10
- BridgeBio Pharma, Inc. operating lease, cost for the quarter ending 2026-06-30 was $1.63M, a 31.72% increase year-over-year.
- BridgeBio Pharma, Inc. operating lease, cost for the quarter ending 2026-03-31 was $1.47M, a 47.48% increase year-over-year.
- BridgeBio Pharma, Inc. operating lease, cost for the quarter ending 2025-12-31 was $1.46M, a 47.23% increase year-over-year.
- BridgeBio Pharma, Inc. operating lease, cost for the quarter ending 2025-09-30 was $1.21M, a 18.23% increase year-over-year.
- BridgeBio Pharma, Inc. operating lease, cost for fiscal 2025 was $4.90M, a 19.27% increase from fiscal 2024.
- BridgeBio Pharma, Inc. operating lease, cost for fiscal 2024 was $4.11M, a 1.93% increase from fiscal 2023.
- BridgeBio Pharma, Inc. operating lease, cost for fiscal 2023 was $4.03M, a 22.04% decline from fiscal 2022.
- BridgeBio Pharma, Inc. operating lease, cost for fiscal 2022 was $5.17M, a 7.82% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.63M 10-Q · filed 2026-08-10 | $3.09M 10-Q · filed 2026-08-10 | $4.55M derived: sum of 3 quarters · filed 2026-08-10 | $5.77M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $1.47M 10-Q · filed 2026-05-07 | $2.92M derived: sum of 2 quarters · filed 2026-05-07 | $4.14M derived: sum of 3 quarters · filed 2026-05-07 | $5.37M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.67M derived: sum of 2 quarters · filed 2026-02-24 | $3.91M derived: sum of 3 quarters · filed 2026-08-10 | $4.90M 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.21M 10-Q · filed 2025-10-29 | $2.45M derived: sum of 2 quarters · filed 2026-08-10 | $3.44M 10-Q · filed 2025-10-29 | $4.43M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.24M 10-Q · filed 2026-08-10 | $2.23M 10-Q · filed 2026-08-10 | $3.22M derived: sum of 3 quarters · filed 2026-08-10 | $4.25M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $994.00K 10-Q · filed 2026-05-07 | $1.99M derived: sum of 2 quarters · filed 2026-05-07 | $3.01M derived: sum of 3 quarters · filed 2026-05-07 | $4.04M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $991.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.02M derived: sum of 2 quarters · filed 2026-02-24 | $3.04M derived: sum of 3 quarters · filed 2026-02-24 | $4.11M 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.03M 10-Q · filed 2025-10-29 | $2.05M derived: sum of 2 quarters · filed 2025-10-29 | $3.12M 10-Q · filed 2025-10-29 | $4.13M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $1.02M 10-Q · filed 2025-08-05 | $2.09M 10-Q · filed 2025-08-05 | $3.10M derived: sum of 3 quarters · filed 2026-02-24 | $4.10M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $1.07M 10-Q · filed 2025-04-29 | $2.08M derived: sum of 2 quarters · filed 2026-02-24 | $3.08M derived: sum of 3 quarters · filed 2026-02-24 | $4.07M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.01M derived: sum of 2 quarters · filed 2026-02-24 | $3.00M derived: sum of 3 quarters · filed 2026-02-24 | $4.03M 10-K · filed 2026-02-24 |
| 2023-09-30 | $1.00M 10-Q · filed 2024-11-12 | $1.99M derived: sum of 2 quarters · filed 2024-11-12 | $3.02M 10-Q · filed 2024-11-12 | $4.18M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $992.00K 10-Q · filed 2024-08-01 | $2.02M 10-Q · filed 2024-08-01 | $3.18M derived: sum of 3 quarters · filed 2025-02-20 | $4.31M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $1.03M 10-Q · filed 2024-05-02 | $2.19M derived: sum of 2 quarters · filed 2025-02-20 | $3.31M derived: sum of 3 quarters · filed 2025-02-20 | $4.66M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $2.28M derived: sum of 2 quarters · filed 2025-02-20 | $3.63M derived: sum of 3 quarters · filed 2025-02-20 | $5.17M 10-K · filed 2025-02-20 |
| 2022-09-30 | $1.13M 10-Q · filed 2023-11-02 | $2.47M derived: sum of 2 quarters · filed 2023-11-02 | $4.02M 10-Q · filed 2023-11-02 | $5.55M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $1.34M 10-Q · filed 2023-08-03 | $2.89M 10-Q · filed 2023-08-03 | $4.42M derived: sum of 3 quarters · filed 2024-02-22 | $5.88M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $1.54M 10-Q · filed 2023-05-04 | $3.08M derived: sum of 2 quarters · filed 2024-02-22 | $4.54M derived: sum of 3 quarters · filed 2024-02-22 | $5.79M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.99M derived: sum of 2 quarters · filed 2024-02-22 | $4.25M derived: sum of 3 quarters · filed 2024-02-22 | $5.61M 10-K · filed 2024-02-22 |
| 2021-09-30 | $1.46M 10-Q · filed 2022-11-03 | $2.71M derived: sum of 2 quarters · filed 2022-11-03 | $4.08M 10-Q · filed 2022-11-03 | $5.18M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $1.26M 10-Q · filed 2022-08-04 | $2.62M 10-Q · filed 2022-08-04 | $3.72M derived: sum of 3 quarters · filed 2023-02-23 | $4.72M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $1.36M 10-Q · filed 2022-05-05 | $2.47M derived: sum of 2 quarters · filed 2023-02-23 | $3.46M derived: sum of 3 quarters · filed 2023-02-23 | $4.46M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $2.10M derived: sum of 2 quarters · filed 2023-02-23 | $3.09M derived: sum of 3 quarters · filed 2023-02-23 | $3.79M 10-K · filed 2023-02-23 |
| 2020-09-30 | $995.00K 10-Q · filed 2020-11-05 | $1.99M derived: sum of 2 quarters · filed 2021-08-05 | $2.68M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $995.00K 10-Q · filed 2021-08-05 | $1.69M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $694.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |